Haigh, J.E.; Patel, K.; Rack, S.; Jiménez-Labaig, P.; Betts, G.; Harrington, K.J.; Metcalf, R.
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Curr. Oncol. 2024, 31, 5652-5661.
https://doi.org/10.3390/curroncol31090419
AMA Style
Haigh JE, Patel K, Rack S, Jiménez-Labaig P, Betts G, Harrington KJ, Metcalf R.
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Current Oncology. 2024; 31(9):5652-5661.
https://doi.org/10.3390/curroncol31090419
Chicago/Turabian Style
Haigh, Joseph Edward, Karan Patel, Sam Rack, Pablo Jiménez-Labaig, Guy Betts, Kevin Joseph Harrington, and Robert Metcalf.
2024. "The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers" Current Oncology 31, no. 9: 5652-5661.
https://doi.org/10.3390/curroncol31090419
APA Style
Haigh, J. E., Patel, K., Rack, S., Jiménez-Labaig, P., Betts, G., Harrington, K. J., & Metcalf, R.
(2024). The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Current Oncology, 31(9), 5652-5661.
https://doi.org/10.3390/curroncol31090419
